|
|
| |
Nakahara N,Kobayashi M, Mano T, Nakamura J. System Dynamics Simulation for Acute Schizophrenia Treatment. ISPOR 15th Annual International Meeting, 18 May, 2010, Atlanta, GA, USA. (Poster presentation) |
|
Kobayashi M. German situation. ISPOR Japan Chapter 2009 Annual Meeting. 13 May, 2010, Tokyo, Japan. (Seminar “Economic evaluation in healthcare policy making.”) (in Japanese) |
|
Kamae I,Kobayashi M. Value-based pricing of new drugs in Japan using the principle of incremental cost-effectiveness ratio. ISPOR 12th Annual European Congress, 27 October, 2009, Paris, France. (Workshop) |
|
| Kamae I,Kobayashi M, Togawa D, Konno S. Cost-utility analysis of balloon kyphoplasty for patients with osteoporotic vertebral compression fractures in Japan. ISPOR 12th Annual European Congress, 24-27 October, 2009, Paris, France. (Poster presentation) |
|
| Ikeda S,Kobayashi M, Tajima N. Cost-effectiveness analysis of voglibose for prevention of type-2 diabetes mellitus in Japanese individuals with impaired glucose tolerance. ISPOR 12th Annual European Congress, 24-27 October, 2009, Paris, France. (Poster presentation) |
|
| Kobayashi M. The concept of health economic evaluation. The 47th Annual Congress of Japan Society for Healthcare Administration. 18 October, 2009, Tokyo, Japan. (ISPOR Japan Chapter Special Symposium “Medical policy making and health economics evaluation”) (in Japanese) |
|
Ikeda S,Kobayashi M. Evaluation of long-term prognosis model of type-2 diabetes mellitus. 52nd Annual meeting of the Japan Diabetes Society. 21 May, 2009, Osaka, Japan. (Poster presentation) (in Japanese) |
|
| Konno S, Togawa D, Kamae I, Inoue S, Kikuchi S. Burden of illness of conservative medical management of osteoporotic vertebral compression fractures in Japan. ISPOR 14th Annual International Meeting, 18 May, 2009, Orlando, FL, USA. (Poster presentation) |
|
Ikeda S, Ikeda K, Yamagishi H, Maeyama K, Miura M, Yokoyama T, Morikawa Y, Shiro H, Kobayashi M. Evaluation of hospitalization cost of RS virus infection. JSPE Conference 2008, 7-9 November 2008. (in Japanese) |
|
Ikeda S, Kobayashi M. Tajima N. Cost-effectiveness analysis of voglibose in prevention of type2 diabetes with impaired glucose tolerance(IGT). JSPE Conference 2008, 7-9 November 2008. (in Japanese) |
|
Inoue S, Kobayashi M, Sugaya K. Economic impact of Overactive Bladder symptoms in Japan. ISPOR 3rdAsia-pacific conference, 7-9 September, 2008, Seoul, Korea |
|
Ikeda S, Kobayashi M, Tajima N. Cost-effectiveness analysis of voglibose in prevention of type2 diabetesin Japanese with impaired glucose tolerance (IGT). ISPOR 3rdAsia-pacific conference, 7-9 September 2008, Seoul, Korea.
|
|
| Ikeda S, Kobayashi M, Makino H. Cost-effectiveness of the use of Angiotensin-Ⅱ recepter blockers in patients with type 2 diabetes and nephropathy in Japan. ISPOR 13th annual international meeting, 3-7 May , 2008, Toronto, Canada. |
|
Kobayashi M, Ikeda S, Yamauchi K. Estimation of CVD risk in a Japanese population using a Framingham risk equation. Jpn J Med Info. 2005;25(Suppl.)1246-1248. (in Japanese) |
|
|
Saito I, Kobayashi M , Matsushita Y, Kawasugi K, Saruta T. Pharmacoeconomic analysis of Ca antagonist and with DIU treatment. The 28th annual scientific meeting of the Japanese society of hypertension 2000. (in Japanese) |
|
|
Saito I, Kobayashi M, Matsushita Y, Kawasugi K, Saruta T. Pharmacoeconomic analysis of ARB to effect of kidney protection in high blood pressure of diabetic complications. The 28th annual scientific meeting of the Japanese society of hypertension. 2005. (in Japanese) |
|
|
Inoue T, Kobayashi M, Uetsuka Y, Nakamura S, Fukui T. Cancer chemotherapy and clinical decision analysis. Japan medical treatment pharmacology forum lecture summary collection 2004;12:106. (in Japanese) |
|
|
Kobayashi M, Mano T, Yamauchi K.Research on application to pricing of Pharmacoeconomic analysis. The 24th Joint Conference on Medical Informatics 2004:348-349. (in Japanese) |
|
|
Saito I, Kobayashi M, Kawasugi K, Saruta T. Economic Analysis of antihypertensive agents in treating patients with essential hypertension . The 27th Japanese society of hypertension 2004. (in Japanese) |
|
|
Inoue T, Uetsuka Y, Kobayashi M, Nakamura S. Cancer chemotherapy and clinical decision analysis(2). Japan medical treatment pharmacology forum lecture summary collection. 2003;13:262. (in Japanese) |
|
|
Ota H, Tanno M, Tanaka H, Kobayashi M, Yoshino S. Patient reported outcomes for rheumatoid arthritis in JAPAN. ISPOR first Asia-pacific conference 1-3 September 2003 Kobe, Japan. |
|
|
Tanno M, Ota H, Tanaka H, Kobayashi M, Yoshino S. Caregiver burden for patients with rheumatoid arthritis in Japan. ISPOR first Asia-pacific conference 1-3 September 2003 Kobe, Japan. |
|
|
Ota H, Tanno M, Tanaka H, Kobayashi M, Yoshino S. Correlation between the health assessment questionnaire (HAQ) and utility value rheumatoid arthritis patients. ISPOR first Asia-pacific conference 1-3 September 2003 Kobe, Japan. |
|
|
Kobayashi M , Mano T, Yamauchi K. Different approaches to setting cost data in cost-effectiveness analysis model. The 22nd joint conference on medical informatics(Nov., 2002): 694-695. (in Japanese) |
|
Ikeda S, Kobayashi M. Estimation of long-term prognosis of diabetes mellitus: Development of a risk simulation software for economic evaluation. 45th Annual Meeting of the Japan Diabetes Society, 17 May, Japan. (in Japanese) |
|
|
Ikeda S, Kobayashi M. Cost-effectiveness analysis of glycemic control with pioglitazone hydrochloride for Japanese patients with type II diabetes. Value in Health 2002;Vol.5 No.6:545. |
|
|
Kobayashi M, Gotoh F. Socioeconomic evaluation of cilostazol for the secondary prevention of cerebral infarction in Japan. Value in Health 2000;Vol.3 No.2:69-70. |
|
|
Moriguchi H, Enomoto N, Kobayashi M, Sato C. Evaluation of management strategies of hepatitis C virus 1B. A decision analysis. Hepatology 1999;Vol.30 No.4 Pt.2:265A. |
|
|
H Moriguchi, M Kobayashi, J Tazawa, C Sato. A decision analysis of management strategies for polypoid lesions of the gallbladder. Medical Decision Making 1998;Vol.18 No.4:485. |
|
 |
|
|
